USPTO Patent Applications - Therapeutics (A61P)

Pyridazinone PARP Inhibitor Compounds, Azkarra Therapeutics, 23rd Apr

The USPTO published patent application US20260109686A1, filed by Azkarra Therapeutics, Inc. on 2023-10-02 (Application No. 19117032), covering pyridazin-3(2H)-one and pyridin-2(1H)-one core compounds designed to inhibit PARP proteins, particularly PARP7, for treating diseases responsive to PARP inhibition. Competitors developing PARP inhibitors should treat this publication as prior art and conduct freedom-to-operate analyses. Researchers and investors monitoring oncology therapeutic pipelines should note Azkarra's expanded intellectual property position in the PARP inhibitor space.

Muscarinic Receptor Allosteric Modulators, University of Toledo, 23rd Apr

The University of Toledo has published patent application US20260109674A1 covering allosteric modulators of muscarinic receptors and methods of making and using the same, filed on October 23, 2023. The application names six inventors: William S. Messer Jr., Hazel Cunningham, Corey Widman, John Ellis, Isaac Schiefer, and Gina Kaup. This publication makes the technical disclosure publicly available, establishing priority date without granting enforceable rights until and unless the application issues as a granted patent.

Novel Compounds Promote Hair Growth and Inflammatory Disorder Inhibition

Chang Gung University of Science and Technology has published patent application US20260109682A1, filed October 20, 2024, covering novel compounds with structures of formula (I), (II), or (III) for promoting hair growth or inhibiting inflammatory disorders including acute respiratory distress syndrome and acute liver injury. The compounds or their pharmaceutically acceptable salts may be used to manufacture pharmaceutical compositions for the stated therapeutic indications. This A1 publication makes the application publicly available; patent prosecution and any resulting grant remain pending.

Quinoline RAGE Modulators, New York University, Apr 23

New York University filed patent application US20260109684A1 on September 27, 2023, covering quinoline compounds as modulators of RAGE (Receptor for Advanced Glycation End-products) activity. The published application discloses pharmaceutical compositions and dosage forms containing these quinoline compounds for preventing and treating conditions including diabetes complications, inflammation, neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease, and COVID-19 complications. The application names Ann Marie Schmidt, Michaele Maningrasso, Ravichandran Ramasamy, Alexander Shekhtman, and Robert DeVita as inventors.

Oleic Acid Derivatives as Treatments for Friedreich Ataxia and Ferroptosis Inhibitors

The USPTO published patent application US20260109661A1 on April 23, 2026, filed by The Trustees of the University of Pennsylvania. The application covers oleic acid derivatives of Formula I or Formula II, compositions containing them, and methods of use for treating neurodegenerative disorders including Friedreich ataxia, as well as compounds acting as ferroptosis inhibitors. Seven inventors are named: Amos Smith, Robert B. Wilson, Donna M Huryn, Maria Grazia Cotticelli, Shujuan Xia, Taehee Lee, and Roberto Forestieri.

Mosunetuzumab Subcutaneous Dosing Patent Application for B Cell Disorders

The USPTO has published patent application US20260109777A1, filed June 25, 2025 (Application No. 19249597), titled 'Methods of Treating Cancer Using Subcutaneous Dosing of Mosunetuzumab as a Monotherapy or in Combination with Lenalidomide.' The application covers methods for treating CD20-positive B cell proliferative disorders including non-Hodgkin's lymphomas and chronic lymphocytic leukemia via subcutaneous administration of mosunetuzumab, alone or combined with lenalidomide. Named inventors include Samuel Dean Tracy, Hong Wang, Jue Wang, Brendan Christian Bender, and 13 others. This published application represents an early-stage intellectual property filing and does not yet constitute an issued patent grant.

Beta Adrenergic Agonist Patent Application US20260109671A1

USPTO published patent application US20260109671A1 on April 23, 2026, filed September 24, 2025 under Application No. 19339240. The application covers chemical compounds for beta adrenergic agonist use and methods of treating diseases associated with adrenergic receptors. Inventors include Anthony P. Ford, Wei Chen, David Scott Carter, and Jiaxin Yu. CPC classifications indicate therapeutic applications for neurological conditions including A61P 25/16 (antiparkinson drugs) and A61P 25/28 (anti-Alzheimer agents).

Docking Peptides for Targeted Antibody Drug Conjugates

USPTO published patent application US20260109780A1 filed by inventors John K. Cini and Nick Evans on April 22, 2025, covering novel docking peptides and antibody-based drug conjugates designed for enhanced targeted delivery of drug payloads to tumor microenvironments with controlled drug-to-antibody ratios. The application includes CPC classifications indicating therapeutic applications for cancer treatment (A61P 35/00).

Bispecific Antibodies BCMA-CD3 Reduce Alloantibody Pre-Transplant

USPTO has published patent application US20260109772A1, filed October 9, 2023 under Application No. 19116305, covering methods for desensitizing solid organ transplant candidates using bispecific BCMA-CD3 antibodies. Eight named inventors (Singe, Norton, Harari, Limnander, Sleeman, Perlee, and Carpenter) disclose that the antibodies activate T cells via the CD3 complex in the presence of BCMA-expressing plasma cells, reducing anti-HLA alloantibody levels and calculated panel reactive antibody levels to facilitate transplantation and improve graft survival. CPC classifications include C07K 16/2878 (Fc receptor binding antibodies) and A61P 37/06 (immunological disorder therapeutics).

FAP-Targeted LTBR Antibody Combination for Cancer Treatment

Hoffmann-La Roche Inc. filed US Patent Application US20260109767A1 on December 17, 2025, covering combination therapies using FAP-targeted lymphotoxin beta receptor (LTBR) antibodies and tumor-targeted anti-CD3 bispecific antibodies as T cell engagers for cancer treatment. The application names Roberta Bianchi, Ralf Joerg Hosse, Leo Frederik Kunz, and Pablo Umaña Fernández as inventors. Patent claims are directed to the antibody combinations and methods of treating cancer using these therapies.

LAG-3 Antagonist Melanoma Treatment

The USPTO published patent application US20260109766A1 for LAG-3 antagonist therapy for treating melanoma, filed September 12, 2025 by inventors Shivani SRIVASTAVA and Mena ABASKHAROUN. The application covers methods of treating unresectable or metastatic melanoma using a LAG-3 antagonist, optionally in combination with a CTLA-4 inhibitor and/or additional anti-cancer therapies.

Multi-Specific Antibodies Binding A33 Antigen and DOTA Metal Complex for Colorectal Cancer

The USPTO published patent application US20260109765A1 filed by six named inventors covering multi-specific binding agents that bind A33 glycoprotein antigen and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), along with methods for detecting, preventing, and treating diseases expressing the A33 antigen, particularly colorectal cancer. The application was filed on 2025-05-07 and assigned Application No. 19201681. This represents a new intellectual property filing in the targeted cancer therapy space.

US20260109752A1: Extracellular Vesicle Platforms for Therapeutic Delivery

USPTO patent application US20260109752A1 covers platforms for generating extracellular vesicles, compositions of extracellular vesicles, and methods of using extracellular vesicles for therapeutics delivery. The application was filed on October 2, 2025 by inventors Milad Riazifar, Charles Cameron Taylor, and Todd Schurr (application No. 19348356). This is a publication of a patent application, not a granted patent.

University of Texas System Oral Delivery Formulation Patent Application, Apr 23, 2026

The Board of Regents of the University of Texas System has filed USPTO Patent Application US20260108502A1 for oral delivery formulations using self-emulsifying granules and lipid-based granules prepared via additive manufacturing (sintering or melting processes). The compositions form self-emulsifying drug delivery systems and lipid-coated drug particles. This represents a new pharmaceutical composition patent filing; no immediate compliance obligations are imposed.

SH3YL1 Antibodies, Compositions, Diabetic Nephropathy Treatment

USPTO published patent application US20260109755A1 for SH3YL1 monoclonal antibodies and compositions for treating diabetic nephropathy, non-alcoholic steatohepatitis, acute kidney injury, and inflammatory bowel disease. Filed December 16, 2025 under Application No. 19421272 by five named inventors including Yun Soo Bae, Eunjung An, and Jung-Yeon Yoo. The application claims priority for genetic sequences, compositions, and therapeutic methods using SH3YL1 antibodies, but does not yet grant enforceable patent rights.

Multi-Specific Antigen Binding Proteins for Fibrin/VEGF and Eye Treatment

The USPTO published patent application US20260109756A1 on April 23, 2026, disclosing multi-specific antigen binding proteins that bind human fibrin or fibrinogen yC domain and vascular endothelial growth factor (VEGF). Inventors include Kenneth Flanagan, Mathias Rickert, Michael Quigley, and Jeffrey Stavenhagen. The application, originally filed on October 3, 2023 under application number 19117771, covers pharmaceutical compositions and methods of use for treating disorders or conditions of the eye.

ZIP12 Antibody for Hypoxia Diseases, Pulmonary Hypertension, Cancer

The USPTO published patent application US20260109761A1 for ZIP12 antibodies covering compositions, pharmaceutical formulations, kits, and methods for treating and diagnosing hypoxia-related diseases including pulmonary hypertension and cancer. The application, filed on September 24, 2025 under application number 19339013, names inventors Stephanie HOPLEY, Martin WILKINS, and Lan ZHAO. CPC classifications include C07K 16/28 and A61P 9/12, indicating antibody-based therapeutic compositions for cardiovascular indications.

Eye Drop Composition Novel Axitinib Molecular Association

USPTO published patent application US20260108505A1 for an eye drop composition comprising a novel molecular association of axitinib physically bound with solubilizers, stabilizers, and additives including buffers, osmotic pressure regulators, and pH adjusters. The application was filed by SCAI Therapeutics Co., Ltd. on March 4, 2025. CPC classifications include A61K 31/4439, A61K 9/08, and A61P 27/02, indicating a pharmaceutical composition for ophthalmic use.

Neutralizing Antibodies to Human Endothelin-1 for Alport Syndrome Treatment

The USPTO has published Application US20260109760A1, filed October 21, 2025, covering antibodies and functional equivalents capable of neutralizing human endothelin-1. The application names Dominic Cosgrove as inventor and specifies use in treating disease conditions associated with endothelin-1 activation, including Alport syndrome. The patent falls under CPC classifications including C07K 16/26 and A61K 39/3955, indicating therapeutic antibody applications.

Recombinant Bispecific Antibodies Targeting TSLP and IL4R

USPTO published patent application US20260109758A1 on April 23, 2026, disclosing recombinant bispecific antibodies comprising a TSLP binding domain and an IL4R binding domain, invented by Mingjiu Chen, Mark Zhiqing Ma, and Zeyu Peng (Application No. 19114283, filed September 20, 2023). The disclosure covers nucleic acid molecules encoding the antibodies, vectors, host cells, production processes, medical uses, and kits comprising the recombinant bispecific antibodies. CPC classifications include C07K 16/244, C07K 16/2866, and therapeutic indicators A61P 11/06 and A61P 17/00.

Nocendra Inc. Lipoxin Synthesis Patent Application, Apr 23

Nocendra Inc. filed patent application US20260108486A1 on December 17, 2025, covering methods of synthesizing lipoxin analogs (e.g., lipoxin mimetics) and pharmaceutical compositions comprising these pro-resolving compounds. The application lists Thomas E. Van Dyke and Charles N. Serhan as inventors. The published application includes CPC classifications A61K 31/202 and A61P 1/02.

Siponimod and Beta-Blocker Combination for Treating Autoimmune Disease

The USPTO published application US20260108490A1, a method-of-treatment patent covering siponimod in combination with a beta-blocker for treating autoimmune diseases, filed on December 22, 2025. The application names 11 inventors and classifies the invention under CPC categories including A61K (medicinal preparations) and A61P 37/00 (immunoregulating agents). Pharmaceutical companies developing autoimmune disease therapies should review freedom-to-operate positions regarding S1P receptor modulators combined with cardiovascular agents.

Soft Anticholinergic Esters Treat Sialorrhea, Bodor Labs

Bodor Laboratories, Inc. has filed patent application US20260108491A1 (Application No. 19367341, filed October 23, 2025, published April 23, 2026) covering intra-oral formulations of soft anticholinergic alkyl esters for treating excessive drooling associated with sialorrhea. The formulations are described as anhydrous and configured for intra-oral delivery of an effective amount of at least one soft anticholinergic ester to inhibit sialorrhea. CPC classifications include A61K 31/40 (heterocyclic compounds), A61P 1/02 (stomatological preparations), and C07D 207/10 and C07D 207/12 (pyrrole derivatives).

Neuroinnovatech Parkinson's Non-Motor Symptoms Therapeutic Agent, Apr 23, 2026

NEUROINNOVATECH ApS has filed USPTO patent application US20260108494A1 for a therapeutic agent targeting serotonergic or dopaminergic system-related diseases, specifically the mental dysfunction and non-motor symptoms of Parkinson's disease. The application includes a treatment and recurrence-prevention method using a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. Application No. 19423150 was filed on 2025-12-17 with inventors Taro Kato and Satoko Shimizu.

Nasal Pharmaceutical Composition Treats Chronic Rhinosinusitis

The USPTO has published patent application US20260108489A1, filed October 15, 2025 by inventors Eduardo Roberto Varizat and Daniel Roberto Varizat, covering a new topical nasal pharmaceutical composition for the treatment and prophylaxis of chronic rhinosinusitis (CRS). The composition comprises a homogeneous aqueous suspension containing Rifamycin, fluticasone propionate, oxymetazoline hydrochloride, bacterial antigens, 0.9% saline solution, and pharmaceutical excipients, formulated for nasal spray administration. The inventors claim synergy among the active ingredients producing local antibiotic, anti-inflammatory, decongestant, and immunomodulatory effects at the site of action.

Reprogramming Exhausted T Cells, Boosting Cancer Immunotherapy

USPTO published patent application US20260108496A1 disclosing methods for reviving exhausted T cells and enhancing cancer immunotherapy by inhibiting TGFβR1 and/or BMP4 proteins, or using agonists to rescue functional phenotypes of exhausted T cells. The application was filed on 2023-09-14 under application number 19111688 and published on 2026-04-23. Inventors include Hazem Ghoneim.

Pelthos Therapeutics Injectable Extended-Release Formulation for Pain Treatment

USPTO published patent application US20260108499A1 for Pelthos Therapeutics Inc., filed October 22, 2025, covering injectable pharmaceutical formulations for extended release comprising 2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide, or a pharmaceutically acceptable salt thereof. The named inventors are Eric D. LANG, Simon Paul CHANDLER, Deshou JIANG, and Richard MALAMUT (Application No. 19365336). The formulations are intended for treatment of pain or providing peri-operative anesthesia or post-operative analgesia.

Method of Eradicating Ticks That Attach to Humans Using Lotilaner Formulations

USPTO published patent application US20260108498A1 filed December 22, 2025 (Application No. 19429133) for methods of treating or preventing Lyme disease and other vector-borne diseases via administration of lotilaner, an isoxazoline anti-parasitic therapeutic agent. The application discloses formulations and dosing regimens for eradicating ticks that attach to humans. Named inventors are Bobak Robert Azamian, Douglas Michael Ackermann, Christopher Stivers, and Shawn D. Hickok. CPC classifications indicate pharmaceutical compositions (A61K 31/422, A61K 9/08, A61K 47/26) and antiparasitic applications (A61P 33/14).

Ponesimod Patent with Teriflunomide or Leflunomide

USPTO published Application US20260108501A1 on April 23, 2026, covering a pharmaceutical combination of ponesimod with either teriflunomide or leflunomide. Inventors are Martine Clozel and Laetitia Pouzol, with filing date December 22, 2025, and application number 19429084. The combination is classified under CPC A61P 25/28, indicating neurological therapeutic applications.

Ophthalmic Formulations, Pelthos Therapeutics, Eye Pain

Pelthos Therapeutics Inc. filed US Patent Application US20260108500A1 on October 22, 2025, covering ophthalmic formulations comprising 2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide or a pharmaceutically acceptable salt thereof. The application names four inventors: Eric D. Lang, Simon Paul Chandler, Deshou Jiang, and Richard Malamut. The formulations are directed to treatment of various eye conditions including pain.

Protein or Polypeptide-Loaded Extracellular Vesicle Delivery Platform and Application Thereof

USPTO published patent application US20260108470A1 on April 23, 2026, disclosing a plasmid combination for preparing extracellular vesicles loaded with target proteins or polypeptides, including cGAS and Cre gene plasmids. The application, filed on December 21, 2025 (Application No. 19428281), also covers the extracellular vesicles loaded with these proteins and their use in cancer prevention or treatment. Inventors are Linzhao Cheng, Senquan Liu, and Ding Ma.

Cyr61 in Carbon Nanotubes Restores Bone Density

The Board of Regents of the University of Texas System has filed Application US20260108472A1 for methods and compositions using recombinant Cyr61 carried in carbon nanotubes to restore Cyr61 expression in bone, increase bone density, and treat bone disease. The application was published April 23, 2026 with inventors Xiao-Dong Chen, Milos Marinkovic, and Qiuxia Dai. No compliance obligations or enforcement actions are associated with this patent application publication.

Hemorrhage Prevention Compounds Patent Application

Jesus E. VILLAFRANCA, Charles Richard KISSINGER, and Guohong LI filed Application US20260108481A1 on December 12, 2025, for compounds and methods for the prevention and treatment of hemorrhage and vascular instability. The application, which relates to therapeutic compounds potentially induced by thrombolytic and anti-coagulant therapies, was published on April 23, 2026. The invention is classified under CPC codes including A61K 31/167, A61K 38/482, and A61P 7/04.

PAMAM Nanoparticle Degrades MDM2 and GLUT1 Proteins

USPTO publishes patent application US20260108474A1 for a PAMAM-based nanoparticle protein degradation system targeting MDM2 and GLUT1 proteins for cancer therapy. Invented by Yingshu Guo and Wennan Yan, the system uses silica nanoparticle cores coated with poly(amidoamine) dendrimers linked to three small-molecule ligands. Filed December 19, 2025 and published April 23, 2026, the application claims a cooperative degradation strategy that suppresses tumor cell proliferation and stabilizes p53 protein.

Cyclobenzaprine 5.6mg Daily Transmucosal Fibromyalgia Treatment Patent

USPTO published application US20260108477A1, filed December 16, 2025 (Application No. 19421039), discloses methods for treating fibromyalgia using 5.6mg cyclobenzaprine HCl daily via transmucosal administration in a eutectic form with a basifying agent. The application names Seth Lederman and Gregory M. Sullivan as inventors. CPC classifications include A61K 31/135 (quinoline/dihydroquinoline compounds) and A61P 25/00 (nervous system disorders).

Mitochon Pharmaceuticals 2,4 DNP Cancer Treatment Patent Application

Mitochon Pharmaceuticals, Inc. has filed patent application US20260108476A1 covering compositions and methods for treating cancer using 2,4-DNP (dinitrophenol) and prodrugs thereof. The application, originally filed on August 4, 2022 (Application No. 18681016), was published on April 23, 2026. Named inventors include John Gerard Geisler, Robert Alonso, and Marcelo G. Bonini. The CPC classifications indicate therapeutic applications across multiple drug compound categories (A61K 31/06 through A61P 35/00).

2,3-Dimethoxyquinone Compositions for Preventing Diabetic Retinopathy

USPTO published patent application US20260108483A1 on April 23, 2026, covering methods, compositions, and kits containing substituted 2,3-dimethoxyquinone (Formula I) or a pharmaceutically acceptable salt for preventing progression of diabetic retinopathy, diabetic macular edema, and related retinal disorders. The application names four inventors: Mitchell George Brigell, Ronil Ajaykumar Patel, Jay Stuart Pepose, and Mina Sooch. Filed July 24, 2025 under application number 19279680, the invention is classified under CPC codes A61K 31/192, A61P 9/10, and A61P 27/02.

Mitoxantrone Hydrochloride Liposome for Neuromyelitis Optica Spectrum Disorders Treatment

The USPTO published patent application US20260108478A1 on April 23, 2026, covering mitoxantrone hydrochloride liposome compositions for treating neuromyelitis optica spectrum disorders. The application includes pharmaceutical compositions and methods of treatment, with animal and clinical test results demonstrating safety and efficacy. This represents an early-stage IP filing with no immediate compliance implications for the pharmaceutical sector.

Niclosamide Induces PRX1 Stem Cell Proliferation

USPTO published Patent Application US20260108480A1 on April 23, 2026, filed September 25, 2023, covering methods of inducing proliferation of PRX1-expressing stem cells using niclosamide or its pharmaceutical derivatives. The application names Giuseppe Intini, Luigi Mancinelli, and Xue Hui Geng as inventors. CPC classifications include A61K 31/167, A61K 31/352, A61K 31/4709, and A61P 19/08.

Pregabalin Tablet Treats Neuropathic Pain in Canines

USPTO published patent application US20260108484A1 for a veterinary tablet immediate-release formulation comprising approximately 25% by weight of pregabalin, 5-15% meat flavour, 58-69% microcrystalline cellulose, and 1-2% magnesium stearate as a lubricant, designated for treating neuropathic pain in non-human animals (canines). The application was originally filed on September 8, 2023 (Application No. 19116857) by TriviumVet Designated Activity Company. For pharmaceutical manufacturers, animal health companies, and veterinary drug developers, this publication establishes the priority date and claims scope for freedom-to-operate analysis.

Multi-Modal Nanoprobe Detects Atherosclerotic Plaques

The Sixth Medical Center of Chinese PLA General Hospital filed US Patent Application 19336412 on September 22, 2025, for a multi-modal molecular imaging nanoprobe designated Fe3O4-A12-Cy7. The probe combines fluorescence imaging (FLI), magnetic particle imaging (MPI), and computed tomography angiography (CTA) for early detection and dynamic monitoring of atherosclerotic plaques. Named inventors include Yundai Chen, Mingrui Ma, Yingqian Zhang, Suhui Zhang, Wei Tong, Rundou Chen, Hao Zhou, Zhongxuan Li, and Ziqian Wang.

Cofilin-1 Peptide Drug Enhances Cancer Cell Uptake

The USPTO published patent application US20260108640A1 for a cofilin-1 peptide composition designed to enhance cellular uptake in cancer cells. The peptide mimics endogenous cofilin-1 and incorporates transmembrane amino acid sequences to improve drug delivery, affecting cancer cell migration and invasion while enabling conjugation with chelators for diagnostic imaging. Filed October 22, 2024 under application number 18923581 by inventors Yi-Jang Lee, Min-Ying Lin, Chun-Yi Wu, and Jyh-Der Leu.

Exosome Tracer Complex With Gallium-67/68 Radionuclide and DOTA Chelating Agent

The USPTO published patent application US20260108642A1 on April 23, 2026, disclosing an exosome-based tracer complex incorporating gallium-67 or gallium-68 radionuclides chelated to a bifunctional chelating agent, preferably DOTA. The application was originally filed on December 5, 2024, under application number 18969548, with six inventors named. The invention is classified under A61P 25/28 (CNS disorders) and A61P 35/04 (cancer metastasis), suggesting potential diagnostic imaging applications for neurological conditions and oncology.

Patent for Treating MASLD and MASH Using OCT4, SOX2, KLF4

The USPTO published patent application US20260108630A1 on April 23, 2026, disclosing methods for treating metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) by administering one or more nucleic acids encoding OCT4, SOX2, and KLF4 transcription factors. The application claims the administration may rejuvenate hepatocytes or liver stellate cells and improve symptoms of the liver disease. The four named inventors are Sharon Rosenzweig-Lipson, Ming Yang, Richard Davis, and Michel Wathier, with Application No. 19360504 filed on October 16, 2025.

Spontaneous Metastasis Model Method, 100% mLN Rate

US20260108632A1 is a published patent application disclosing a method for producing a spontaneous metastasis model using recombinant carcinoma cells engineered with luciferase-based expression systems. The disclosed models achieve approximately 100% metastasis incidence for mesenteric lymph node (mLN) invasion and 80–90% for secondary organs, providing statistically significant and robust kinetic data. The application was filed on October 18, 2022, under application number 18292945, with ten named inventors including Amit Sharma and colleagues.

US20260108454A1: Innate Targeting of Adoptive Cellular Therapies

USPTO published patent application US20260108454A1 (filed October 30, 2025) for therapeutic methods involving specific repertoires of PRR ligands to provoke innate immune system signaling and facilitate homing of adoptive immune cells to disease sites, particularly solid tumors. The application names inventors Harold David Gunn, David W. Mullins, Mark Bazett, and Shirin Kalyan. This is a publication of a pending application, not a granted patent.

NIHON SHOKUHIN KAKO Resident Skin Flora Improving Agent

USPTO published patent application US20260108447A1 for a resident-skin-flora-improving agent using sophorose, filed by NIHON SHOKUHIN KAKO CO., LTD. on October 2, 2023. The application discloses that sophorose promotes proliferation of beneficial skin bacteria while suppressing growth of bacteria that could adversely affect the skin, and can be used to maintain balance of resident skin flora.

Methods for Preventing Cardiovascular Events Through PCSK9 Reduction Using RNAi Agents

USPTO published patent application US20260108631A1 filed by inventors David KALLEND and Peter WIJNGAARD on December 22, 2025, covering methods for preventing cardiovascular events through PCSK9 reduction using RNAi agents. The application claims methods of lowering LDL cholesterol, preventing cardiac events in subjects with atherosclerotic cardiovascular disease, and treating such subjects by administering prophylactically or therapeutically effective amounts of an RNAi agent. CPC classifications span A61K (medicinal preparations containing genetic material), C07H (nucleosides/nucleotides), and C12N (mutation/genetic engineering).

L-Ergothioneine Gold Nanoparticles For Medical Applications

Guangzhou First People's Hospital has filed USPTO patent application US20260108633A1 for L-ergothioneine-gold nanoparticles (EGT-AuNPs) combining gold nanoparticle imaging contrast with L-ergothioneine antioxidant properties. The application covers contrast agents and antioxidants for medical imaging and renal protection, particularly early diagnosis and treatment of acute kidney injury (AKI). CPC classifications include A61K 49/04, A61K 9/5192, A61K 31/4172, and A61P 13/12, indicating pharmaceutical compositions for kidney therapy and diagnostic imaging applications.

Epinephrine Prodrug Oral Delivery Patent Application

Aquestive Therapeutics, Inc. has filed US Patent Application US20260108458A1 covering methods of treating allergic symptoms through oral administration of epinephrine and its prodrugs, claiming pharmacokinetic parameters that are improved or comparable to intramuscular injection. The application names Stephen Paul Wargacki, Alexander Mark Schobel, and Carl Neil Kraus as inventors, with a filing date of October 23, 2025. Pharmaceutical companies developing epinephrine delivery formulations should monitor this IP filing for potential freedom-to-operate implications.